Whole blood test results from our Disposable Test Kit (DTK)
The portable rapid M2/M5 quantitative serology machine allows us to protect critical infrastructure in a mobile environment by providing real-time quantitative readout in 15 minutes on a subject’s exact exposure history. This allows us to track down exposed contacts accurately thus preventing work site viral contamination and assessing infectious risk and immunity of the subject. This is for critical Federal work environments such as Armed Services, First Responders, Governmental Agencies, Energy, Power, Engineering, IT, Healthcare, Public Health, Water, Transportation, Telecommunications, etc.
Accurate test results in 10 minutes
Only two steps to operate
1 Kit tests IgM & IgG antibodies
Avoid false negative rates of RT-PCR test
Fingertip blood sample can minimize infection risk
Real-time & on-site spot test, no need for laboratory conditions
Based in California, Watmind USA has a dedicated team of professional healthcare experts in the fields of genomic science, biology and medical device sales.
Our Watmind USA group has decades of international experience in information technologies, regulatory & compliance, research & development, pharmaceutical, medical device, public health, government relations, hospital and laboratory management.
On March 16, 2020, the FDA updated its “Policy for Diagnostic Tests for Coronavirus Disease-2019″ during the Public Health Emergency. (document download)
On March 26, WatMIND USA received its submittal confirmation from the FDA. Under the announced FDA policy, upon filing its submittal, WatMIND USA was authorized to market and distribute “WatMIND USA COVID-19 IgM / IgG Rapid Test Kits” to any licensed healthcare practitioner in the United States for diagnostic use while it awaits a final decision on its FDA EUA application. While the policy does not apply to at-home testing, the policy does allow testing in laboratories or by healthcare workers at the point-of-care.
This test has not been reviewed by the FDA. Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals. Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status. Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43 or 229E.